Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Outcomes and Evaluation of Lotemax (Loteprednol Ophthalmic Solution ) 0.5% QID for Treatment of Ocular Inflammation Associated With Cataract Surgery

NCT01344226 is registered in ClinicalTrials.gov with Toyos Clinic as lead sponsor.

NCT NCT01344226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01344226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Outcomes and Evaluation of Lotemax (Loteprednol Ophthalmic Solution ) 0.5% QID for Treatment of Ocular Inflammation Associated With Cataract Surgery
Lead sponsor
Toyos Clinic
Phase
Observational
Overall status
Completed
Start date
April 30, 2011
Completion date
September 30, 2013
Enrollment
49 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

inflammation, pseudophakia